Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies.

Çakmak-Görür N, Radke J, Rhein S, Schumann E, Willimsky G, Heppner FL, Blankenstein T, Pezzutto A.

Leukemia. 2019 Jan 3. doi: 10.1038/s41375-018-0330-7. [Epub ahead of print] No abstract available.

PMID:
30607022
2.

Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice.

Hoser D, Schön C, Loddenkemper C, Lohneis P, Kühl AA, Sommermann T, Blankenstein T, Willimsky G.

Blood. 2018 Aug 30;132(9):924-934. doi: 10.1182/blood-2018-02-834036. Epub 2018 Jul 12.

PMID:
30002144
3.

Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.

Gavvovidis I, Leisegang M, Willimsky G, Miller N, Nghiem P, Blankenstein T.

Clin Cancer Res. 2018 Aug 1;24(15):3644-3655. doi: 10.1158/1078-0432.CCR-17-2661. Epub 2018 Apr 18.

PMID:
29669806
4.

ERAP1-Dependent Antigen Cross-Presentation Determines Efficacy of Adoptive T-cell Therapy in Mice.

Schmidt K, Keller C, Kühl AA, Textor A, Seifert U, Blankenstein T, Willimsky G, Kloetzel PM.

Cancer Res. 2018 Jun 15;78(12):3243-3254. doi: 10.1158/0008-5472.CAN-17-1946. Epub 2018 Mar 20.

PMID:
29559473
5.

CD96 expression determines the inflammatory potential of IL-9-producing Th9 cells.

Stanko K, Iwert C, Appelt C, Vogt K, Schumann J, Strunk FJ, Ahrlich S, Schlickeiser S, Romagnani C, Jürchott K, Meisel C, Willimsky G, Kühl AA, Sawitzki B.

Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E2940-E2949. doi: 10.1073/pnas.1708329115. Epub 2018 Mar 12.

6.

Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.

Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, Schüssler-Lenz M.

Cancer Immunol Immunother. 2018 Apr;67(4):513-523. doi: 10.1007/s00262-018-2119-y. Epub 2018 Jan 29. Review.

PMID:
29380009
7.

Guidelines for the use of flow cytometry and cell sorting in immunological studies.

Cossarizza A, Chang HD, Radbruch A, Akdis M, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavani A, Chattopadhyay PK, Cheng Q, Chow S, Clerici M, Cooke A, Cosma A, Cosmi L, Cumano A, Dang VD, Davies D, De Biasi S, Del Zotto G, Della Bella S, Dellabona P, Deniz G, Dessing M, Diefenbach A, Di Santo J, Dieli F, Dolf A, Donnenberg VS, Dörner T, Ehrhardt GRA, Endl E, Engel P, Engelhardt B, Esser C, Everts B, Dreher A, Falk CS, Fehniger TA, Filby A, Fillatreau S, Follo M, Förster I, Foster J, Foulds GA, Frenette PS, Galbraith D, Garbi N, García-Godoy MD, Geginat J, Ghoreschi K, Gibellini L, Goettlinger C, Goodyear CS, Gori A, Grogan J, Gross M, Grützkau A, Grummitt D, Hahn J, Hammer Q, Hauser AE, Haviland DL, Hedley D, Herrera G, Herrmann M, Hiepe F, Holland T, Hombrink P, Houston JP, Hoyer BF, Huang B, Hunter CA, Iannone A, Jäck HM, Jávega B, Jonjic S, Juelke K, Jung S, Kaiser T, Kalina T, Keller B, Khan S, Kienhöfer D, Kroneis T, Kunkel D, Kurts C, Kvistborg P, Lannigan J, Lantz O, Larbi A, LeibundGut-Landmann S, Leipold MD, Levings MK, Litwin V, Liu Y, Lohoff M, Lombardi G, Lopez L, Lovett-Racke A, Lubberts E, Ludewig B, Lugli E, Maecker HT, Martrus G, Matarese G, Maueröder C, McGrath M, McInnes I, Mei HE, Melchers F, Melzer S, Mielenz D, Mills K, Mirrer D, Mjösberg J, Moore J, Moran B, Moretta A, Moretta L, Mosmann TR, Müller S, Müller W, Münz C, Multhoff G, Munoz LE, Murphy KM, Nakayama T, Nasi M, Neudörfl C, Nolan J, Nourshargh S, O'Connor JE, Ouyang W, Oxenius A, Palankar R, Panse I, Peterson P, Peth C, Petriz J, Philips D, Pickl W, Piconese S, Pinti M, Pockley AG, Podolska MJ, Pucillo C, Quataert SA, Radstake TRDJ, Rajwa B, Rebhahn JA, Recktenwald D, Remmerswaal EBM, Rezvani K, Rico LG, Robinson JP, Romagnani C, Rubartelli A, Ruckert B, Ruland J, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Sawitzki B, Scheffold A, Schiemann M, Schildberg F, Schimisky E, Schmid SA, Schmitt S, Schober K, Schüler T, Schulz AR, Schumacher T, Scotta C, Shankey TV, Shemer A, Simon AK, Spidlen J, Stall AM, Stark R, Stehle C, Stein M, Steinmetz T, Stockinger H, Takahama Y, Tarnok A, Tian Z, Toldi G, Tornack J, Traggiai E, Trotter J, Ulrich H, van der Braber M, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Volk HD, von Volkmann K, Waisman A, Walker R, Ward MD, Warnatz K, Warth S, Watson JV, Watzl C, Wegener L, Wiedemann A, Wienands J, Willimsky G, Wing J, Wurst P, Yu L, Yue A, Zhang Q, Zhao Y, Ziegler S, Zimmermann J.

Eur J Immunol. 2017 Oct;47(10):1584-1797. doi: 10.1002/eji.201646632. No abstract available.

8.

Oleate but not stearate induces the regulatory phenotype of myeloid suppressor cells.

Wu H, Weidinger C, Schmidt F, Keye J, Friedrich M, Yerinde C, Willimsky G, Qin Z, Siegmund B, Glauben R.

Sci Rep. 2017 Aug 8;7(1):7498. doi: 10.1038/s41598-017-07685-9.

9.

Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Schlenker R, Olguín-Contreras LF, Leisegang M, Schnappinger J, Disovic A, Rühland S, Nelson PJ, Leonhardt H, Harz H, Wilde S, Schendel DJ, Uckert W, Willimsky G, Noessner E.

Cancer Res. 2017 Jul 1;77(13):3577-3590. doi: 10.1158/0008-5472.CAN-16-1922. Epub 2017 May 22.

10.

Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.

Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon PM, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang PA, Lang KS.

Nat Commun. 2017 Mar 1;8:14447. doi: 10.1038/ncomms14447.

11.

Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.

Miller NJ, Church CD, Dong L, Crispin D, Fitzgibbon MP, Lachance K, Jing L, Shinohara M, Gavvovidis I, Willimsky G, McIntosh M, Blankenstein T, Koelle DM, Nghiem P.

Cancer Immunol Res. 2017 Feb;5(2):137-147. doi: 10.1158/2326-6066.CIR-16-0210. Epub 2017 Jan 16.

12.

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.

Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M.

Nature. 2015 May 7;521(7550):94-8. doi: 10.1038/nature14395. Epub 2015 Apr 29.

13.

Adoptive T-cell therapy to treat liver cancer: is the liver microenvironment key?

Willimsky G, Protzer U, Knolle P, Heikenwalder M.

Oncotarget. 2013 Aug;4(8):1117-8. No abstract available.

14.

Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, Blankenstein T.

J Clin Invest. 2013 Mar;123(3):1032-43. doi: 10.1172/JCI64742. Epub 2013 Feb 1.

15.

Fas expression by tumor stroma is required for cancer eradication.

Listopad JJ, Kammertoens T, Anders K, Silkenstedt B, Willimsky G, Schmidt K, Kuehl AA, Loddenkemper C, Blankenstein T.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2276-81. doi: 10.1073/pnas.1218295110. Epub 2013 Jan 22.

16.

Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer.

Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willimsky G.

Blood. 2013 Mar 7;121(10):1740-8. doi: 10.1182/blood-2012-06-436568. Epub 2013 Jan 10.

17.

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.

Pohla H, Buchner A, Stadlbauer B, Frankenberger B, Stevanovic S, Walter S, Frank R, Schwachula T, Olek S, Kopp J, Willimsky G, Stief CG, Hofstetter A, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Mol Med. 2013 Feb 8;18:1499-508. doi: 10.2119/molmed.2012.00221.

18.

The sorting receptor Sortilin exhibits a dual function in exocytic trafficking of interferon-γ and granzyme A in T cells.

Herda S, Raczkowski F, Mittrücker HW, Willimsky G, Gerlach K, Kühl AA, Breiderhoff T, Willnow TE, Dörken B, Höpken UE, Rehm A.

Immunity. 2012 Nov 16;37(5):854-66. doi: 10.1016/j.immuni.2012.07.012. Epub 2012 Oct 16.

19.

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.

Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Jöhrens K, Lukowsky A, Schönemann C, Sawitzki B, Pohla H, Frank R, Dörken B, Schendel DJ, Blankenstein T, Pezzutto A.

Gene Ther. 2011 Apr;18(4):354-63. doi: 10.1038/gt.2010.143. Epub 2010 Nov 11.

PMID:
21068778
20.

The immune response to sporadic colorectal cancer in a novel mouse model.

Czéh M, Loddenkemper C, Shalapour S, Schön C, Robine S, Goldscheid E, Stein H, Schüler T, Willimsky G, Blankenstein T.

Oncogene. 2010 Dec 16;29(50):6591-602. doi: 10.1038/onc.2010.388. Epub 2010 Sep 6.

PMID:
20818425
21.

Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo.

Shalapour S, Deiser K, Sercan O, Tuckermann J, Minnich K, Willimsky G, Blankenstein T, Hämmerling GJ, Arnold B, Schüler T.

Eur J Immunol. 2010 Sep;40(9):2391-400. doi: 10.1002/eji.201040441.

22.

In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance.

Buschow C, Charo J, Anders K, Loddenkemper C, Jukica A, Alsamah W, Perez C, Willimsky G, Blankenstein T.

J Immunol. 2010 Mar 15;184(6):2930-8. doi: 10.4049/jimmunol.0900893. Epub 2010 Feb 8.

23.

Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.

Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Hum Gene Ther. 2010 Mar;21(3):285-97. doi: 10.1089/hum.2008.192.

PMID:
19788391
24.

SV40 large T antigen-transformed human primary normal and cancerous mammary epithelial cells are phenotypically similar but can be distinguished in 3D culture with selection medium.

Li L, Willimsky G, Seitz S, Xu Y, Li Y, Schwarz LE, Schlag PM, Blankenstein T.

Int J Cancer. 2008 Oct 1;123(7):1516-25. doi: 10.1002/ijc.23657.

25.

Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.

Willimsky G, Czéh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, Stein H, Blankenstein T.

J Exp Med. 2008 Jul 7;205(7):1687-700. doi: 10.1084/jem.20072016. Epub 2008 Jun 23.

26.

The adaptive immune response to sporadic cancer.

Willimsky G, Blankenstein T.

Immunol Rev. 2007 Dec;220:102-12. Review.

PMID:
17979842
27.

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Willimsky G, Blankenstein T.

Nature. 2005 Sep 1;437(7055):141-6.

PMID:
16136144
28.

Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.

Frankenberger B, Regn S, Geiger C, Noessner E, Falk CS, Pohla H, Javorovic M, Silberzahn T, Wilde S, Buchner A, Siebels M, Oberneder R, Willimsky G, Pezzutto A, Blankenstein T, Schendel DJ.

World J Urol. 2005 Jul;23(3):166-74. Epub 2005 Jul 5. Review.

PMID:
15997395
29.

Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.

Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, Kopp J, Oberneder R, Blankenstein T, Schendel DJ.

Clin Cancer Res. 2005 Mar 1;11(5):1733-42.

30.

Tumor-induced antibodies resemble the response to tissue damage.

Preiss S, Kammertoens T, Lampert C, Willimsky G, Blankenstein T.

Int J Cancer. 2005 Jun 20;115(3):456-62.

31.

Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes.

Scholz C, Stärck L, Willimsky G, Blankenstein T, Dörken B, Daniel PT.

Gene Ther. 2002 Nov;9(21):1438-46.

32.

Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse.

Schendel DJ, Frankenberger B, Jantzer P, Cayeux S, Nöbetaner E, Willimsky G, Maget B, Pohla H, Blankenstein T.

Gene Ther. 2000 Dec;7(23):2007-14.

33.

Allogeneic vaccination for renal cell carcinoma: development and monitoring.

Pohla H, Frankenberger B, Stadlbauer B, Oberneder R, Hofstetter A, Willimsky G, Pezzutto A, Dörken B, Blankenstein T, Schendel DJ.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S83-7.

PMID:
10933197
34.
35.

RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes.

Uckert W, Willimsky G, Pedersen FS, Blankenstein T, Pedersen L.

Hum Gene Ther. 1998 Nov 20;9(17):2619-27.

PMID:
9853528
36.

Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells.

Aicher A, Westermann J, Cayeux S, Willimsky G, Daemen K, Blankenstein T, Uckert W, Dörken B, Pezzutto A.

Exp Hematol. 1997 Jan;25(1):39-44.

PMID:
8989905
37.

Mapping of the Bacillus subtilis cspB gene and cloning of its homologs in thermophilic, mesophilic and psychrotrophic bacilli.

Schröder K, Zuber P, Willimsky G, Wagner B, Marahiel MA.

Gene. 1993 Dec 22;136(1-2):277-80.

PMID:
8294017
38.

Structure in solution of the major cold-shock protein from Bacillus subtilis.

Schnuchel A, Wiltscheck R, Czisch M, Herrler M, Willimsky G, Graumann P, Marahiel MA, Holak TA.

Nature. 1993 Jul 8;364(6433):169-71.

PMID:
8321289
39.
40.

Overproduction, crystallization, and preliminary X-ray diffraction studies of the major cold shock protein from Bacillus subtilis, CspB.

Schindelin H, Herrler M, Willimsky G, Marahiel MA, Heinemann U.

Proteins. 1992 Sep;14(1):120-4.

PMID:
1409560

Supplemental Content

Loading ...
Support Center